Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
42 hedge funds and large institutions have $108M invested in Evelo Biosciences, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 16 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 42 → 42 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
9% less capital invested
Capital invested by funds: $118M → $108M (-$10.1M)
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.46M |
| 2 |
BlackRock
New York
|
+$90.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$70.1K |
| 4 |
LFG
Larson Financial Group
St Louis,
Missouri
|
+$60.8K |
| 5 |
Millennium Management
New York
|
+$54.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$2.57M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$103K |
| 3 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$78K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$72K |
| 5 |
Barclays
London,
United Kingdom
|
-$44.4K |
EVLO Hedge Fund Activity: Q1 2020 in Review
42 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q1 2020, worth a combined $108M — down 8.5% from $118M a quarter earlier.
Fund positioning in EVLO was balanced in Q1 2020: 3 funds opened new positions, 3 closed out, 13 added to existing stakes and 16 trimmed.
The largest buyer was Credit Suisse, adding an estimated $1.46M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $2.57M sold.
- 42 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $108M of Evelo Biosciences, Inc. Common Stock stock for Q1 2020, down 8.5% quarter-over-quarter.
- 3 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q1 2020 and 3 closed out, a net change of 0 holders.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q1 2020 was Credit Suisse, an estimated $1.46M added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q1 2020 was Sectoral Asset Management, an estimated $2.57M sold.
Based on aggregated 13F filings for Q1 2020.